HLN Stock Analysis: Buy, Sell, or Hold?
HLN - Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$8.96
0.05 (0.56%)
▲
5d:
-1.65%
30d:
-6.57%
90d:
-20.0%
HOLD
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: Jul 30, 2026
Get Alerted When HLN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: HLN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: HLN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.68
Based on 6.7% avg growth
INTRINSIC VALUE TODAY
$9.11
1.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HLN is currently trading at $8.96, which is considered oversold relative to its 30-day fair value range of $9.14 to $9.78. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.7) compared to its historical average (17.4). Remarkably, the market is currently pricing in an annual earnings decline of 5.5% over the next few years. This pessimistic expectation contrasts with the company's recent 92.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, HLN is in a strong downtrend. The price is currently testing key support at $8.89. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: HLN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.74 (+31.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, HLN is in a strong downtrend. The price is currently testing key support at $8.89. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: HLN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.74 (+31.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$9.14 -
$9.78
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 31.0% below Wall St target ($11.74)
Trading Range Analysis
30-Day Trading Range
$9.14 -
$9.78
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$8.89
Resistance Level
$9.37
Current Trend
Strong Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.68
Wall Street Target
$11.74
(+31.0%)
Revenue Growth (YoY)
0.6%
Earnings Growth (YoY)
92.0%
Profit Margin
15.1%
Valuation Discount vs History
-5.5% cheaper
PE vs Historical
14.7 vs 17.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.5%
(market-implied from PE analysis)
1-Year Target
$8.47
(-6%)
2-Year Target
$8.00
(-11%)
3-Year Target
$7.56
(-16%)
3-Yr Target (if PE normalizes)
(PE: 15→17)
$8.96
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.1, Growth: 9.4%)
$17.64
(+97%)
Base:
(SPY PE: 14.7, Growth: 9.4%)
$11.73
(+31%)
Bear:
(PE: 12.5, Growth: 9.4%)
$9.97
(+11%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 17.82 | Current EPS (TTM): $0.50
Bull Case
$11.97
(+34%)
Analyst growth 22.1%, PE expands to 19.6
Base Case
$10.88
(+21%)
Market implied 22.1%, PE stable at 17.8
Bear Case
$6.06
(-32%)
Severe decline -20.0%, PE contracts to 15.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.7 to 17.4
Stabilization Target:
$10.62
(+18.5%)
PE Expansion Potential:
+18.5%
Share & Embed Analysis
Last updated: May 16, 2026 3:14 AM ET
Data refreshes hourly during market hours. Next update: 4:14 AM
Data refreshes hourly during market hours. Next update: 4:14 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HLN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$136 | 57 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$102 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 58 HOLD |
